Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) covers the month of August 2002, specifically dated August 7, 2002. The report announces a significant intellectual property development regarding the company's antiplatelet drug, Plavix(R).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a current report focused on a patent grant rather than a financial statement.
Material Changes and Developments
- Patent Grant: Sanofi was granted U.S. Patent 6,429,210 for the crystalline polymorphic Form 2 of clopidogrel bisulfate, the active ingredient in Plavix(R).
- Patent Term: The new patent was filed in June 1999, issued on August 6, 2002, and extends to 2019.
- Regulatory Action: The company intends to notify the U.S. FDA to ensure the patent is listed in the Orange Book.
- Existing Litigation: Current patents covering all forms of clopidogrel bisulfate, which are subject to litigation, expire in 2011 and 2014.
Outlook, Risks, and Management Commentary
Management emphasizes a vigorous defense of Plavix patents in collaboration with alliance partner Bristol-Myers Squibb. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to several factors:
- Ability to expand profitably in the United States.
- Success of research and development programs.
- Ability to protect intellectual property rights.
- Risks associated with healthcare cost reimbursement and pricing reforms, particularly in the U.S. and France.
Investor Verification Checklist
- Verify the listing of U.S. Patent 6,429,210 in the FDA's Orange Book.
- Monitor the status of ongoing litigation regarding the patents expiring in 2011 and 2014.
- Assess the impact of pricing reforms and reimbursement policies in the U.S. and France on Plavix revenue.
- Review the progress of the alliance with Bristol-Myers Squibb in defending intellectual property.